A concerning new study reveals that prescription stimulant misuse in US affects one in four American adults who use these medications, with amphetamine-based drugs showing particularly high rates of problematic use.

The research, analysing data from over 83,000 adults aged 18-64, found that 25.3% of those using prescription stimulants reported misuse, whilst 9% developed prescription stimulant use disorder (PSUD). Perhaps most alarmingly, nearly half of those with PSUD showed no obvious signs of prescription drug abuse in US, making identification challenging for healthcare providers.

Amphetamines Present Higher Risk

The study uncovered striking differences between stimulant types. Adults using amphetamine-based medications were 3.1 times more likely to engage in prescription stimulant misuse in US compared to those taking methylphenidate. They also faced 2.2 times higher odds of developing prescription stimulant use disorder.

Among those with PSUD, 87.1% were using amphetamines, and remarkably, 72.9% were solely using their own prescribed medications rather than obtaining drugs from other sources. This challenges traditional assumptions about prescription drug abuse in US patterns.

Middle-Aged Women Drive Prescription Surge

The most dramatic increase in stimulant prescriptions occurred among women aged 35-64, with numbers rising from 1.2 million in early 2019 to 1.7 million by late 2022. This represents a 2.6% average quarterly increase, suggesting growing recognition of attention disorders in this demographic.

Interestingly, this same group showed the lowest rates of prescription stimulant misuse in US at 13.7%, compared to younger adults where misuse rates reached 36.8% among women aged 18-25.

Silent Struggle: When Prescription Becomes Problem

The research highlights a troubling reality: 42.5% of those with prescription stimulant use disorder reported no misuse behaviours, indicating that dependency can develop even when medications are taken as prescribed. This finding suggests that traditional screening methods may miss significant numbers of people struggling with prescription drug abuse in US.

“Stay alert, stay aware” – healthcare providers must remain vigilant for signs of dependency regardless of how patients report using their medications. The study emphasises that screening should occur for all adults prescribed stimulants, not just those showing obvious signs of misuse.

Clinical Implications and Prevention

The findings underscore the importance of comprehensive monitoring throughout treatment. Healthcare providers need robust protocols for identifying prescription stimulant misuse in US and PSUD, particularly among amphetamine users who face elevated risks.

The research suggests that “prevention beats intervention” – establishing clear guidelines for prescribing, monitoring, and discontinuing stimulants could help reduce problematic use patterns before they develop into full disorders.

Most cases of PSUD were classified as mild (63.6%), suggesting that early intervention strategies could be particularly effective in preventing progression to more severe forms of prescription drug abuse in US.

What’s Next for Prescribing Practices

As stimulant prescriptions continue rising, particularly among middle-aged women seeking treatment for previously undiagnosed attention disorders, healthcare systems must balance improved access to necessary medications with robust safeguards against prescription stimulant misuse.

The study’s authors call for evidence-based clinical guidance and enhanced training for healthcare providers on the benefits and risks of prescription stimulants for adults, emphasising that both appropriate prescribing and addiction prevention can coexist.

Source: JAMA Network